|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02877 SHINEWAY PHARM
Nominal 
7.570 -0.170 (-2.196%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 3,778,043 | -16.351% | 4,516,538 | 3,950,636 | 3,223,550 | 2,655,701 |
| Cost of Sales | (946,294) | -15.692% | (1,122,419) | (1,012,322) | (813,214) | (667,855) |
| Gross Profit | 2,831,749 | -16.569% | 3,394,119 | 2,938,314 | 2,410,336 | 1,987,846 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | (4,073) | |
| Change in FV & Impairment on Others | (6,612) | 21.544% | (5,440) | (8,828) | (7,021) | (232,443) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 1,145,721 | -7.622% | 1,240,253 | 917,025 | 720,103 | 395,024 | |
| Taxation | (305,669) | 12.900% | (270,743) | (194,252) | (163,429) | (99,991) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 840,052 | -13.353% | 969,510 | 722,773 | 556,674 | 295,033 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (170,589) | 84.480% | (92,470) | (91,801) | (93,812) | (71,226) |
| Depreciation & Amortisation | 68,735 | 14.115% | 60,233 | 58,686 | 63,661 | 49,160 |
| Directors' Emoluments | 14,122 | -66.628% | 42,317 | 11,849 | 10,319 | 9,153 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 111.000 | -13.281% | 128.000 | 96.000 | 74.000 | 39.000 |
| DPS (cts) | 54.000 | -- | 42.000 | 32.000 | 39.000 | 32.000 |
| Dividend Payout Ratio (%) | 48.649% | -- | 32.813% | 33.333% | 52.703% | 82.051% |
| Cash flow per share ($) | -- | -- | 1.235 | 1.469 | 0.931 | 0.844 |
| NBV per share ($) | 9.029 | -- | 8.506 | 7.718 | 7.136 | 7.006 |
| Remarks: | Real time quote last updated: 16/04/2025 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 840,052 |
| %Change | -13.353% |
| EPS / (LPS) | RMB 1.110 |
| NBV Per Share (¥) | RMB 9.029 |